Program
zamicastat
Also written as “BIA 5-1058”, “Oral zamicastat” and “400 mg BIA 5-1058”.
Its studies are mostly in Pulmonary Arterial Hypertension · Cardiovascular Diseases · Hypertension, led by Bial - Portela C.
Furthest: phase 2, since Mar 18, 202013 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bial - Portela C | 130 open or running | phase 2since Mar 18, 2020 | May 26, 2014 | none ahead |
Also a collaborator on its studies: covance.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 26, 2014First study: phase 1 study in HypertensionFirst studyNCT02151994 · 124 enrolled · Netherlands
- Mar 29, 2018Phase 1 study in Cardiovascular DiseasesNCT03489005 · 49 enrolled · United Kingdom
- Oct 12, 2018Phase 1 study in Pulmonary Arterial HypertensionNCT03708146 · 157 enrolled · United Kingdom
- Mar 18, 2020Phase 2 study in Pulmonary Arterial HypertensionNCT04316143 · 33 enrolled · Austria, Germany, Italy and more
- Dec 15, 2020Phase 1 study in Pulmonary Arterial HypertensionNCT04675944 · 20 enrolled · Germany
- Jul 28, 20216 phase 1 studies in Pulmonary Arterial HypertensionNCT04991207, NCT04991194, NCT04991181 and 3 more
- Jul 17, 2023Phase 2 study in Pulmonary Arterial HypertensionNCT06009185 · 20 enrolled · Austria, Germany, Italy and more
- Sep 8, 2025Phase 1 study in Pulmonary Arterial HypertensionNCT07173738 · 44 enrolled · United Kingdom
TargetBeta
DBH →read by rule
“Dopamine beta-hydroxylase inhibitor”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07173738Pulmonary Arterial Hypertension · United Kingdom | 1 | Completed | Sep 7, 2018 | 44 |
| NCT06009185Pulmonary Arterial Hypertension · Austria, Germany, Italy and more | 2 | Completed | Feb 17, 2022 | 20 |
| NCT04994860Pulmonary Arterial Hypertension · Germany | 1 | Completed | Jun 7, 2018 | 20 |
| NCT04994119Pulmonary Arterial Hypertension · Germany | 1 | Completed | May 23, 2018 | 26 |
| NCT04991207Pulmonary Arterial Hypertension · Germany | 1 | Completed | May 14, 2018 | 44 |
| NCT04991194Pulmonary Arterial Hypertension | 1 | Terminated | Dec 30, 2016 | 61 |
| NCT04991181Pulmonary Arterial Hypertension · Netherlands | 1 | Completed | May 24, 2017 | 15 |
| NCT04991155Pulmonary Arterial Hypertension | 1 | Completed | Sep 22, 2015 | 57 |
| NCT04675944Pulmonary Arterial Hypertension · Germany | 1 | Completed | May 25, 2018 | 20 |
| NCT04316143Pulmonary Arterial Hypertension · Austria, Germany, Italy and more | 2 | Completed | Oct 20, 2021 | 33 |
| NCT03708146Pulmonary Arterial Hypertension · United Kingdom | 1 | Completed | Mar 18, 2019 | 157 |
| NCT03489005Cardiovascular Diseases · United Kingdom | 1 | Completed | Oct 5, 2018 | 49 |
| NCT02151994Hypertension · Netherlands | 1 | Completed | Jan 2012 | 124 |
How it is read
Names in the registry
- “BIA 5-1058”, 10 entries
- “Oral zamicastat”, 2 entries
- “400 mg BIA 5-1058”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 11 studies
- Cardiovascular Diseases, 1 study
- Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.